Jeremy Guehennec
Overview
Explore the profile of Jeremy Guehennec including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
211
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verreault M, Vilchis I, Rosenberg S, Lemaire N, Schmitt C, Guehennec J, et al.
Clin Transl Med
. 2022 Jul;
12(7):e939.
PMID: 35808822
Objective: New therapeutic approaches are needed to improve the prognosis of glioblastoma (GBM) patients. Methods: With the objective of identifying alternative oncogenic mechanisms to abnormally activated epidermal growth factor receptor...
2.
Drean A, Lemaire N, Bouchoux G, Goldwirt L, Canney M, Goli L, et al.
J Neurooncol
. 2019 Jun;
144(1):33-41.
PMID: 31197598
Introduction: Glioblastoma (GBM) is the most common and aggressive primary brain cancer in adults. Few cytotoxic chemotherapies have been shown to be effective against GBM, due in part to the...
3.
Drean A, Rosenberg S, Lejeune F, Goli L, Nadaradjane A, Guehennec J, et al.
J Neurooncol
. 2018 Mar;
138(3):487.
PMID: 29549621
The names of authors Marc Sanson and Jean-Yves Delattre were incorrectly presented in the initial online publication. The original article has been corrected.
4.
Drean A, Rosenberg S, Lejeune F, Goli L, Nadaradjane A, Guehennec J, et al.
J Neurooncol
. 2018 Mar;
138(3):479-486.
PMID: 29520610
ATP-binding cassette transporters (ABC transporters) regulate traffic of multiple compounds, including chemotherapeutic agents, through biological membranes. They are expressed by multiple cell types and have been implicated in the drug...
5.
Rosenberg S, Verreault M, Schmitt C, Guegan J, Guehennec J, Levasseur C, et al.
Neuro Oncol
. 2016 Aug;
19(2):219-228.
PMID: 27571888
Background: Glioblastoma (GBM) is the deadliest primary brain cancer in adults. Emerging innovative therapies hold promise for personalized cancer treatment. Improving therapeutic options depends on research relying on relevant preclinical...
6.
Drean A, Goldwirt L, Verreault M, Canney M, Schmitt C, Guehennec J, et al.
Expert Rev Neurother
. 2016 Jun;
16(11):1285-1300.
PMID: 27310463
Glioblastomas (GBM) are the most common and aggressive primary malignant brain tumors in adults. The blood brain barrier (BBB) is a major limitation reducing efficacy of anti-cancer drugs in the...
7.
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, et al.
Clin Cancer Res
. 2015 Oct;
22(5):1185-96.
PMID: 26482041
Purpose: p53 pathway alterations are key molecular events in glioblastoma (GBM). MDM2 inhibitors increase expression and stability of p53 and are presumed to be most efficacious in patients with TP53...